133 related articles for article (PubMed ID: 19579441)
1. [About quality registries: are we afraid the results will not be the ones we wanted?].
Thernlund G
Lakartidningen; 2009 May 20-Jun 2; 106(21-22):1496; author reply 1496. PubMed ID: 19579441
[No Abstract] [Full Text] [Related]
2. [Attention deficit hyperkinetic syndrome (ADHS) and stimulants].
Rothenberger A
Z Kinder Jugendpsychiatr Psychother; 2002 Aug; 30(3):159-61. PubMed ID: 12227218
[No Abstract] [Full Text] [Related]
3. Attention-deficit hyperactivity disorder, methylphenidate, and primary encopresis.
Golubchik P; Weizman A
Psychosomatics; 2009; 50(2):178. PubMed ID: 19377031
[No Abstract] [Full Text] [Related]
4. Hyperactivity and inattention--a successful response to table coffee.
Wammanda RD
Niger J Clin Pract; 2007 Jun; 10(2):182-3. PubMed ID: 17902517
[No Abstract] [Full Text] [Related]
5. Advances in the pharmacotherapy of attention-deficit/hyperactivity disorder.
Kollins SH; March JS
Biol Psychiatry; 2007 Nov; 62(9):951-3. PubMed ID: 17950067
[No Abstract] [Full Text] [Related]
6. Focalin XR for ADHD.
Med Lett Drugs Ther; 2009 Mar; 51(1308):22-4. PubMed ID: 19305368
[No Abstract] [Full Text] [Related]
7. Attention deficit hyperactivity disorder in prison.
Ghanizadeh A; Akhondzadeh S
J Am Acad Psychiatry Law; 2009; 37(2):278. PubMed ID: 19535565
[No Abstract] [Full Text] [Related]
8. Atomoxetine may improve methylphenidates' efficacy in treatment of ADHD?
Niederhofer H
Psychiatr Danub; 2009 Sep; 21(3):330. PubMed ID: 19794351
[No Abstract] [Full Text] [Related]
9. Attention deficit hyperactivity disorder in prison: a treatment protocol.
Appelbaum KL
J Am Acad Psychiatry Law; 2009; 37(1):45-9. PubMed ID: 19297632
[TBL] [Abstract][Full Text] [Related]
10. Stimulants, ADHD, and the heart.
Ganiats TG
Am Fam Physician; 2009 May; 79(10):846, 851. PubMed ID: 19496384
[No Abstract] [Full Text] [Related]
11. [Methylphenidate. A drug for attention deficit disorders to be used with precaution].
Taéron C
Rev Infirm; 2009 Jun; (151):47-9. PubMed ID: 19579855
[No Abstract] [Full Text] [Related]
12. Authors' response to letter regarding the WA regulatory scheme for stimulants.
Calver J; Sanfilippo F; Preen D; Bulsara M
Aust N Z J Public Health; 2008 Aug; 32(4):395. PubMed ID: 18782409
[No Abstract] [Full Text] [Related]
13. Attention-deficit/hyperactivity disorder. Questions and controversies.
Smoyak SA
J Psychosoc Nurs Ment Health Serv; 2008 Aug; 46(8):8-9. PubMed ID: 18777963
[No Abstract] [Full Text] [Related]
14. Response to Calver et al. on the WA regulatory scheme for stimulants.
Stevens M
Aust N Z J Public Health; 2008 Apr; 32(2):182. PubMed ID: 18412693
[No Abstract] [Full Text] [Related]
15. [Without treatment the crash threatens].
Einecke U
MMW Fortschr Med; 2009 Jan; 151(5):14-6. PubMed ID: 19391404
[No Abstract] [Full Text] [Related]
16. Cardiovascular safety of medication treatments for attention-deficit/hyperactivity disorder.
Newcorn JH; Donnelly C
Mt Sinai J Med; 2009 Apr; 76(2):198-203. PubMed ID: 19306385
[No Abstract] [Full Text] [Related]
17. What exactly are the benefits of stimulants for ADHD?
Advokat C
J Atten Disord; 2009 May; 12(6):495-8. PubMed ID: 19380518
[No Abstract] [Full Text] [Related]
18. The role of pharmacotherapy and managed care pharmacy interventions in the treatment of ADHD.
Dopheide JA
Am J Manag Care; 2009 May; 15(5 Suppl):S141-50. PubMed ID: 19601689
[TBL] [Abstract][Full Text] [Related]
19. [Therapy of ADHD. British institute recommends: drugs only in severe cases].
Matthis M
MMW Fortschr Med; 2009 Feb; 151(7):16. PubMed ID: 19432257
[No Abstract] [Full Text] [Related]
20. [Malnutrition in children with DAMP?].
Andersen LL
Ugeskr Laeger; 2009 Mar; 171(10):824. PubMed ID: 19280776
[No Abstract] [Full Text] [Related]
[Next] [New Search]
